All In Biotech

Drug Trial Radar · NCT04674800

Extension Study of MYL-1701P-3001 for Safety and Efficacy

A Multi Center, Extension Study to Evaluate the Safety and Efficacy of MYL-1701P in Subjects With Diabetic Macular Edema Completed MYL-1701P-3001 Study.

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

52

Actual

Start

Nov 23, 2020

Primary completion

Apr 20, 2022

Study completion Apr 20, 2022

Sponsor

Lead sponsor
Mylan Pharmaceuticals IncIndustry
Sponsor type
Industry
Collaborators
Momenta Pharmaceuticals, Inc.
First posted
Dec 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Study (AFIL-IJZ-3002) is designed to evaluate the safety, efficacy and immunogenicity of MYL-1701P among a group of participants successfully completing MYL-1701P-3001 (NCT03610646) study.

Conditions

  • Diabetic Macular Edema

Interventions

  • MYL-1701P, a proposed biosimilar to EyleaBiological

    MYL-1701P- 3 doses each of 2 mg at 8 weeks interval

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment Emergent Adverse Events (TEAEs).Time frame: Week 20

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Mylan Investigative site

    Hyderabad, Andhra Pradesh, India

  • Mylan Investigative Site

    Visakhapatnam, Andhra Pradesh, India

  • Mylan Investigative Site

    Ahmedabad, Gujarat, India

  • Mylan Investigative site

    Ahmedabad, Gujarat, India

  • Mylan Investigative site

    Bangalore, Karnataka, India

  • Mylan Investigative Site

    Bangalore, Karnataka, India

  • Mylan Investigative Site

    Bengaluru, Karnataka, India

  • Mylan Investigative Site

    Mumbai, Maharashtra, India

  • Mylan Investigative site

    New Delhi, New Delhi, India

  • Mylan Investigative site

    Bhubaneswar, Odisha, India

  • Mylan Investigative Site

    Chandigarh, Punjab, India

  • Mylan Investigative site

    Jaipur, Rajasthan, India

  • Mylan Investigative site

    Madurai, Tamil Nadu, India

  • Mylan Investigative site

    Tirunelveli, Tamil Nadu, India

  • Mylan Investigative Site

    Noida, Uttar Pradesh, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.